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Purpose: Tumour volumetric changes can be observed during 
radical chemo-radiotherapy (CRT) for locally advanced non-small 
cell lung cancer (NSCLC); but it is unclear whether these changes 
are predictive of outcomes. This study aims to a) examine 
whether the magnitude of tumour regression is correlated with 
disease control and survival; b) explore the potential difference 
between adenocarcinoma (AC) and non-adenocarcinoma (non-
AC) NSCLC subtypes.  
Methods and Materials: Primary tumour volumes were recorded 
and analyzed on weekly serial cone beam computed tomography 
(CBCT) images of NSCLC patients treated with CRT from January 
2006 to June 2007 at our institution1. Tumour volume regression 
was divided into three categories: < 10%, 10-30%, and ≥ 30%. 
Outcome measures included locoregional failure-free survival 
(LRFFS), distant failure-free survival (DFFS), and overall survival 
(OS), which were calculated using the Kaplan-Meier method. 
Univariate analysis (UVA) and multivariate analysis (MVA) of 
LRFFS, DFFS and OS were performed using the Cox regression 
model. Further analysis was performed comparing AC and non-
AC subgroups. 
Results: Forty-five patients with Stage II-III NSCLC were 
included. Median age was 64 years (range: 43 – 79 years). Median 
follow up was 22.1 months for all patients, and 90 months for 
alive patients (range: 0.9-108 months). The distribution of 7th 
Ed. AJCC stage was as follows: Stage IIB (T3N0) 8.9%; IIIA 66.7%; 
IIIB 24.4%. Twenty patients (44.4%) had AC, while 25 patients 
(55.6%) had non-AC histologies. All patients received concurrent 
chemotherapy. Twenty-eight patients (62.3%) received a total 
radiation dose of ≥ 60 Gy, 15 patients (33.3%) received 45 Gy as 
part of trimodality therapy determined upfront, and two patients 
(4.4%) received 58-59 Gy due to missed fractions. Among all 45 
patients, 23 patients (51.1%) had ≥ 30% regression by fraction 15 
and 32 patients (71.1%) by treatment completion. In UVA for all 
patients, young age (p = 0.02) and AC histology (p = 0.03) were 
significantly associated with better LRFFS; young age was 
significantly associated with better DFFS (p = 0.048) and OS (p = 
0.04). For patients with AC histology, MVA showed that ≥ 30% 
regression by fraction 15 and younger age were significantly 
associated with better LRFFS (p = 0.007, 0.006 respectively), 
DFFS (p = 0.007, 0.004), and OS (p = 0.02, 0.004). For patients 
with non-AC histology, ≥30% regression by treatment completion 
was significantly associated with better LRFFS (p = 0.02), but 
none of the factors had any significant correlation with DFFS or 
OS.  
Conclusions: Evaluation of primary tumour regression on CBCT 
images during CRT may be predictive of treatment response. 
Early tumour regression, as indicated by ≥30% regression by 
fraction 15, was shown to be associated with better outcomes 
for adenocarcinoma histologic subtype in our study. This 
observation may provide insight into when, how and in which 
patients to best utilize adaptive radiotherapy.  
1. J Thorac Oncol. 2011; 6: 531-6. 
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Purpose: Non-small cell lung cancer (NSCLC) is the most common 
primary cancer to metastasize to the brain. However, the 
incidence or likelihood of developing brain metastasis, after 
initial diagnosis and treatment, is generally unknown, as 
provincial population-based cancer registries do not routinely 
capture metastatic relapses. At our centre, a retrospective 
cohort study has gathered longitudinal clinical data for all NSCLC 
patients consulted since 1999 (Glans-Look Lung Cancer 
Database). In this report, we describe the cumulative incidence 
of brain metastasis observed for NSCLC patients diagnosed 
between 1999 and 2010. 
Methods and Materials: Clinical data, including date of brain 
metastasis diagnosed by CT/MR imaging, is abstracted from 
electronic and paper charts by full time research coordinators. 
De novo cases of brain metastasis were defined as positive CT/MR 
within 30 days of initial cancer diagnosis and distinguished from 
relapsing cases (Stages I-IV at initial diagnosis). Cumulative 
incidence of relapsing brain metastasis was computed, stratified 
by cancer stage at initial diagnosis and adjusted for competing 
risk of death before developing brain metastasis. Survival 
difference between de novo and relapsing brain metastasis 
(those initially Stage I-III) was examined by pre-specified 
proportional hazard regression model, adjusting for age and year 
of diagnosis.  
Results: A total of 5,264 NSCLC incident cases diagnosed 
between 1999 and 2010 were identified and analyzed (90% have 
died). Median age at initial cancer diagnosis was 70 years. 
Proportion of Stage I, II, III and IV patients was 18%, 8.3%, 20% 
and 54% respectively. A total of 451 patients relapsed with brain 
metastasis, giving a five-year cumulative incidence of 8.6%, 14% 
and 8.0% for Stage I-II, Stage III, and Stage IV, respectively. 
Among the 2,827 Stage IV patients, 631 (22%) and 179 (6.3%) had 
de novo and relapsing brain metastasis, respectively. Median 
survival of de novo brain metastasis (n = 631, 3.2 months, CL 2.8-
3.5 months) was worse than that for Stage I-III relapsing cases (n 
= 272, 3.9 months, CL 3.3-4.7 months), adjusted HR 1.24, CL 
1.07-1.44 months. 
Conclusions: The five-year cumulative incidence of brain 
metastasis was 8.6%, 13%, and 8.0% among Stage I-II, Stage III 
and Stage IV NSCLC patients. Twenty-two percent of Stage IV 
NSCLC patients presented with de novo brain metastasis, whose 
median survival was significantly worse than that for Stage I-III 
patients with relapsing brain metastasis. 
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Purpose: Kaposi sarcoma (KS) is a non-curable malignancy which 
can present with cutaneous lesions. Some patients with KS can 
have a long indolent chronic course. Radiotherapy is often used 
to help palliate local symptoms for cutaneous lesions which bleed 
or cause pain. 
Methods and Materials: A retrospective review was undertaken 
for all KS patients treated with radiotherapy at our centre from 
January 2, 1999 to December 31, 2014 (inclusive). This study was 
approved by the local hospital Research Ethics Board. 
Demographic information (date of birth, gender, co-morbidities) 
were retrieved along with radiotherapy details, symptoms, 
treatment side-effects and outcomes. 
Results:  A total of 48 patients with KS (44 classical, 0 endemic, 
one iatrogenic, three AIDS related) were seen in our 
multidisciplinary skin clinic during this study period. Eighteen 
patients received radiotherapy to 107 sites (1-20 sites per 
patient). There were five females and 13 males. Ages at the time 
of initial radiotherapy ranged from 44-93 years of age. 
Radiotherapy dose ranged from 6 Gy in 1 fraction to 30 Gy in 10 
fractions with the most common scheme being 8 Gy in 1 fraction 
or 20 Gy in 5 fractions. Of the 107 sites treated, 106 showed 
regression of the KS lesions with benefit in terms of pain, 
swelling or bleeding. One site in the posterior leg showed 
progressive KS despite 8 Gy in 1 fraction which continued to 
bleed and ulcerate. Two patients had initial partial response to 
radiotherapy but had relapse within the radiated fields requiring 
repeat radiotherapy. One patient had relapse within the radiated 
fields and subsequently was observed. No fatal toxicities 
occurred. The most common side effects were dry 
desquamation, hyperpigmentation and lymphedema of the legs. 
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Conclusions:  Low dose radiotherapy provides effect palliation 
of distressing symptoms resulting from cutaneous KS with 
acceptable toxicity. 
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Purpose: Consider a 2x2x1.5 cm basal cell cancer invading right 
medial canthus periocular embryonic fusion plane. Usual 
techniques fail: an irregular PTV 4x4x2.5 cm deep, a concave 
surface, a deep tumour, and adjacent ocular structures. 
Oculoplastics/Mohs risk enucleation. Electrons with an internal 
eye shield require bolus and limit energy to 9 MeV. High energy 
conformal RT risks medial retinal damage. Systemic agents may 
palliate but do not cure. We describe low energy electron RT (e-
) with an orthovoltage (ortho) bump. “Bump” modulates energy 
by replacing some e-dose with ortho to increase surface dose and 
optimize dose distribution. Bump applies to any anatomic 
location to a depth of 2-3 cm. Bump can use e- with a tungsten 
eye shield and ortho for maximal eye-sparing. With orbit 
invaded, morbidity follows. Radiotherapy may be the best eye-
preserving option. 
Methods and Materials: Central-axis dose calculation using 
measured % depth dose were compared with central and off-
central axis dose calcs using kVDoseCalc, a dose engine validated 
in kV cone-beam and ortho therapy; and Monte Carlo for e- off-
axis dose calc. We compare conformal RT, arcs, and bump, for 
periocular cancer cases. We compared central axis data for a 4x4 
cm field with: 1) 9 MeV alone; 2) 9 MeV with 0.7 cm custom wax; 
3) 9 MeV, 80% of dose, 100 kV DXR bump, SSD 10 cm, 20% of dose; 
4) 9 MeV, 80% of dose, 200 kV DXR bump, SSD 50 cm, 20% of dose. 
Patients treated at our institution in 10 or 20 treatments 
received 8 or 16 electron treatments (prescribed to account for 
REB of electrons) and 2 or 4 photons treatments, for a total dose 
of 45 Gy in 10 fractions, or 50 Gy in 20 fractions. 
Results: For the case above tables based on measured dose give: 
Surface dose (1) 86%; (2) 90%; (3) 100%; (4) 94% 
Dmax (100%) (1) 2.0 cm; (2) 1.3 cm; (3) 2.0 cm; (4) 2.0 cm  
Dose @ 2.7 cm (1) 89%; (2) 58%; (3) 87%; (4) 91% 
Surface and depth refer to skin surface. Dose is normalized: 
Dmax = 100%. REB and geometry are not included. Comparing 
dynamic conformal ARCs, VMAT, electrons +/- bolus or tantalum 
mesh, and bump show the benefits of 9 MeV with 100-200 kV 
bump. Dose drop off is swift at ~40%/cm beyond D90%. Dose 
spares eye. Low SSD, low kV bump results in best homogeneity 
and surface dose; high kV bump gives best dose at depth. 
Patients can be scanned with a 3D printer wax replica eye shield 
to reduce artifact and enable accurate dose calculation. Actual 
patient results are illustrated with isodose distributions; for 
three clinical cases, the dose above 80% to retina was 2.5 cc for 
conformal treatment, 1.0 cc for dynamic conformal arc and < 0.5 
cc for bumps, demonstrating excellent shielding for the bump 
technique. 
Conclusions: Energy modulation with ortho and electrons can 
result in improved dose distribution. Benefits include: increased 
treatment depth, improved dose homogeneity, no bolus, 
increased shield effectiveness, and reduced penumbra; 
important when treating near the eye. 
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Purpose: Chemical exchange saturation transfer magnetic 
resonance imaging (CEST MRI) represents a novel technique for 
detecting cell death in vivo, without the need for injected 
exogenous contrast media or lengthy wait times (as with 
standard anatomical assessment of tumour response). Changes in 
CEST signal parameters corresponding to amide, amine, and 
aliphatic tissues have been suggested to correlate with necrosis. 
In this study, we sought to characterize the changes in CEST 
parameters over time to help determine the optimal time point 
to detect cell death. 
Methods and Materials: CEST MRI data were acquired from 
xenografted MDA-231 breast cancer tumours (n = 12) before and 
after injection with doxorubicin (100 mg/m2) and paclitaxel (50 
mg/m2) chemotherapy. Tumours were scanned at baseline and 
three different treatment times - 4, 8, and 12 hours after 
injection.  
Acquired data was fitted to Lorentzian shapes using a previously 
described method. The peak amplitude is measured as a unitless 
ratio of the measured signal to the CEST signal of bulk water; 
area under the curve is in units of parts per million (ppm), 
related to the resonant frequency of measured protons. Baseline 
CEST parameters were compared to parameters at each 
treatment time using two-tailed T tests with p-value for 
significance of ≤ 0.05. 
Results: For the aliphatic peak, amplitude measured 0.063 ± 
0.009 at baseline, 0.066 ± 0.009 at four hours, 0.095 ± 0.013 at 
8 hours, and 0.065 ± 0.019 at 12 hours post-injection; only the 
change from baseline to eight hours was statistically significant 
(p = 0.02). Significant change in area under the curve (0.051 ± 
0.014 to 0.115 ± 0.015 ppm; p = 0.006) was also observed at eight 
hours post-injection but not at four or 12 hours. For the amine 
peak, significant changes in amplitude were observed at eight 
hours (p < 0.001) and 12 hours (p < 0.001) post-injection; 
amplitude change was not significant at four hours nor was any 
change in peak area at any time point. For the amide peak, no 
significant differences were seen from baseline at any time point 
for peak amplitude or area. 
Conclusions: Our results suggest that eight hours after injection 
of chemotherapy may represent the optimal time to measure cell 
death using CEST MRI, as significant changes were observed in 
aliphatic and amine peak amplitudes at this time point. 
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Purpose: Tumour hypoxia is an adverse prognostic factor in many 
cancers. 18F-FAZA is a hypoxia tracer, which can provide a non-
invasive method of hypoxia imaging with PET, but has not been 
widely studied in NSCLC. This study aims to evaluate the 
feasibility and potential benefits of using 18F-FAZA-PET scans to 
assess NSCLC tumour hypoxia.  
Methods and Materials: Thirteen of the planned 20 patients with 
Stage II – III NSCLC are included thus far in this prospective study 
by imaging with FAZA-PET before initiation of radical chemo- 
radiotherapy. Patients were imaged two hours post-injection 
with FAZA. Attenuation correction was performed using a helical 
computed tomography (hCT) for respiratory gated PET (gPET). 
The exhale bin was used for analysis for the purpose of this study. 
The hypoxic volume (HV) was defined as all voxels within the 
tumour with standard uptake value (SUV) more than three 
standard deviations from the mean values obtained from muscle 
SUV as defined by Mortensen et al. 2012. The Tmax/Mmean ratio 
was defined as maximum tumour SUV divided by the mean 
erector spinae muscle SUV. The hypoxic fraction (HF) was 
determined by dividing the HV by the entire gross tumour volume 
(GTV). Pearson correlation (rho) was performed to evaluate 
whether some of these metrics are correlated.  
Results: A hypoxic volume (HV) in the primary tumour was 
identified in 12 patients (92.3%). The hypoxic fraction (HF) 
